BIO-TECHNE Corp (TECH) Free cash flow
- Free cash flow · 12 months (USD): Value $263.22M; Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value 21.66%; Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | $263.22M | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. $292.07M − $28.85M ≈ $263.22M |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | 21.66% | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. $263.22M ÷ $1.22B × 100 ≈ 21.66% |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $292.07M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | (m) | Operating cash flow / net income. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | 292.07M USD | Net Cash Provided by (Used in) Operating Activities · Net Cash Provided by (Used in) Operating Activities, Continuing Operations |
| Capital spending | 28.85M USD | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | 263.22M USD | Net Cash Provided by (Used in) Operating Activities · Net Cash Provided by (Used in) Operating Activities, Continuing Operations · Payments to Acquire Property, Plant, and Equipment |
| Revenue | 1.22B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | (m) | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $263.22M | (m) | $292.07M | $28.85M | (m) | $1.22B | (m) | (m) | (m) | (m) | 21.66% | (m) |
| 2026-03-31 | $269.60M | (m) | $294.86M | $25.26M | (m) | $1.21B | (m) | $109.56M | (m) | (m) | 22.27% | 2.69× |
| 2025-12-31 | $223.02M | (m) | $249.32M | $26.30M | (m) | $1.22B | (m) | $81.10M | (m) | (m) | 18.35% | 3.07× |
| 2025-09-30 | $224.06M | (m) | $251.25M | $27.20M | (m) | $1.22B | (m) | $77.98M | (m) | (m) | 18.41% | 3.22× |
| 2025-06-30 | $256.55M | (m) | $287.56M | $31.01M | (m) | $1.22B | (m) | $73.40M | (m) | (m) | 21.03% | 3.92× |
| 2025-03-31 | $220.75M | (m) | $264.85M | $44.10M | (m) | $1.21B | (m) | $131.67M | (m) | (m) | 18.26% | 2.01× |
| 2024-12-31 | $254.30M | (m) | $304.72M | $50.41M | (m) | $1.20B | (m) | $158.14M | (m) | (m) | 21.26% | 1.93× |
| 2024-09-30 | $245.03M | (m) | $303.49M | $58.46M | (m) | $1.17B | (m) | $150.71M | (m) | (m) | 20.91% | 2.01× |
| 2024-06-30 | $236.10M | (m) | $298.98M | $62.88M | (m) | $1.16B | (m) | $168.10M | (m) | (m) | 20.37% | 1.78× |
| 2024-03-31 | $251.15M | (m) | $306.88M | $55.73M | (m) | $1.15B | (m) | $203.00M | (m) | (m) | 21.76% | 1.51× |
| 2023-12-31 | $225.39M | (m) | $276.43M | $51.03M | (m) | $1.14B | (m) | $224.16M | (m) | (m) | 19.68% | 1.23× |
| 2023-09-30 | $215.41M | (m) | $257.69M | $42.28M | (m) | $1.14B | (m) | $246.70M | (m) | (m) | 18.83% | 1.04× |
| 2023-06-30 | $216.15M | (m) | $254.39M | $38.24M | (m) | $1.14B | (m) | $285.26M | (m) | (m) | 19.02% | 0.89× |
| 2023-03-31 | $232.73M | (m) | $273.72M | $40.98M | (m) | $1.12B | (m) | $271.30M | (m) | (m) | 20.71% | 1.01× |
| 2022-12-31 | $251.97M | (m) | $296.31M | $44.34M | (m) | $1.12B | (m) | $261.82M | (m) | (m) | 22.50% | 1.13× |
| 2022-09-30 | $284.52M | (m) | $332.92M | $48.39M | (m) | $1.12B | (m) | $291.99M | (m) | (m) | 25.46% | 1.14× |
| 2022-06-30 | $280.36M | (m) | $325.27M | $44.91M | (m) | $1.11B | (m) | $272.05M | (m) | (m) | 25.36% | 1.20× |
| 2022-03-31 | $301.92M | (m) | $344.57M | $42.65M | (m) | $1.08B | (m) | $225.49M | (m) | (m) | 28.05% | 1.53× |
| 2021-12-31 | $308.16M | (m) | $346.31M | $38.16M | (m) | $1.03B | (m) | $210.53M | (m) | (m) | 29.93% | 1.64× |
| 2021-09-30 | $295.16M | (m) | $334.59M | $39.43M | (m) | $984.55M | (m) | $176.63M | (m) | (m) | 29.98% | 1.89× |
| 2021-06-30 | $307.86M | (m) | $352.16M | $44.30M | (m) | $931.03M | (m) | $140.41M | (m) | (m) | 33.07% | 2.51× |
| 2021-03-31 | $224.58M | (m) | $274.94M | $50.36M | (m) | $847.84M | (m) | $184.29M | (m) | (m) | 26.49% | 1.49× |
| 2020-12-31 | $200.50M | (m) | $249.54M | $49.04M | (m) | $798.97M | (m) | $174.95M | (m) | (m) | 25.09% | 1.43× |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | $759.65M | (m) | $248.30M | (m) | (m) | (m) | (m) |
| 2020-06-30 | $153.47M | (m) | $205.22M | $51.74M | (m) | $738.69M | (m) | $229.30M | (m) | (m) | 20.78% | 0.89× |
| 2020-03-31 | $170.31M | (m) | $216.37M | $46.06M | (m) | $754.52M | (m) | $186.91M | (m) | (m) | 22.57% | 1.16× |
| 2019-12-31 | $164.86M | (m) | $206.56M | $41.71M | (m) | $744.70M | (m) | $195.13M | (m) | (m) | 22.14% | 1.06× |
| 2019-09-30 | $150.96M | (m) | $182.71M | $31.75M | (m) | $734.28M | (m) | $93.07M | (m) | (m) | 20.56% | 1.96× |
| 2019-06-30 | $156.21M | (m) | $181.62M | $25.41M | (m) | $714.01M | (m) | $96.07M | (m) | (m) | 21.88% | 1.89× |
| 2019-03-31 | $170.97M | (m) | $190.51M | $19.54M | (m) | (m) | (m) | $121.31M | (m) | (m) | (m) | 1.57× |
| 2018-12-31 | $154.38M | (m) | $172.50M | $18.12M | (m) | (m) | (m) | $96.40M | (m) | (m) | (m) | 1.79× |
| 2018-09-30 | $145.27M | (m) | $165.12M | $19.85M | (m) | (m) | (m) | $127.69M | (m) | (m) | (m) | 1.29× |
| 2018-06-30 | $149.43M | (m) | $170.37M | $20.93M | (m) | (m) | (m) | $126.15M | (m) | (m) | (m) | 1.35× |
| 2018-03-31 | $135.12M | (m) | $156.10M | $20.98M | (m) | (m) | (m) | $112.06M | (m) | (m) | (m) | 1.39× |
| 2017-12-31 | $137.98M | (m) | $159.47M | $21.49M | (m) | $599.38M | (m) | $114.49M | (m) | (m) | 23.02% | 1.39× |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | $577.03M | (m) | $73.11M | (m) | (m) | (m) | (m) |
| 2017-06-30 | $128.27M | (m) | $143.45M | $15.18M | (m) | $563.00M | (m) | $76.09M | (m) | (m) | 22.78% | 1.89× |
| 2017-03-31 | $116.62M | (m) | $128.98M | $12.37M | (m) | $541.19M | (m) | $69.61M | (m) | (m) | 21.55% | 1.85× |
| 2016-12-31 | $130.00M | (m) | $141.18M | $11.19M | (m) | $528.12M | (m) | $78.51M | (m) | (m) | 24.61% | 1.80× |
| 2016-09-30 | $125.32M | (m) | $138.54M | $13.22M | (m) | $517.22M | (m) | $98.05M | (m) | (m) | 24.23% | 1.41× |
| 2016-06-30 | $126.97M | (m) | $143.87M | $16.90M | (m) | $499.02M | (m) | $104.48M | (m) | (m) | 25.44% | 1.38× |
| 2016-03-31 | $123.87M | (m) | $144.65M | $20.78M | (m) | $481.92M | (m) | $105.18M | (m) | (m) | 25.70% | 1.38× |
| 2015-12-31 | $115.42M | (m) | $138.29M | $22.87M | (m) | $465.11M | (m) | $99.18M | (m) | (m) | 24.82% | 1.39× |
| 2015-09-30 | $114.35M | (m) | $135.47M | $21.12M | (m) | $456.15M | (m) | $106.53M | (m) | (m) | 25.07% | 1.27× |
| 2015-06-30 | $119.45M | (m) | $139.36M | $19.91M | (m) | $452.25M | (m) | $107.73M | (m) | (m) | 26.41% | 1.29× |
| 2015-03-31 | $125.07M | (m) | $140.14M | $15.07M | (m) | $427.11M | (m) | $108.23M | (m) | (m) | 29.28% | 1.29× |
| 2014-12-31 | $129.89M | (m) | $144.30M | $14.41M | (m) | $408.50M | (m) | $115.58M | (m) | (m) | 31.80% | 1.25× |
| 2014-09-30 | $124.98M | (m) | $139.90M | $14.91M | (m) | $380.57M | (m) | $107.43M | (m) | (m) | 32.84% | 1.30× |
| 2014-06-30 | $122.94M | (m) | $136.76M | $13.82M | (m) | $357.76M | (m) | $110.95M | (m) | (m) | 34.36% | 1.23× |
| 2014-03-31 | $111.76M | (m) | $128.83M | $17.07M | (m) | $344.71M | (m) | $112.53M | (m) | (m) | 32.42% | 1.14× |
| 2013-12-31 | $107.74M | (m) | $126.92M | $19.18M | (m) | $330.15M | (m) | $114.01M | (m) | (m) | 32.63% | 1.11× |
| 2013-09-30 | $103.13M | (m) | $126.88M | $23.75M | (m) | $321.22M | (m) | $114.32M | (m) | (m) | 32.11% | 1.11× |
| 2013-06-30 | $101.11M | (m) | $123.56M | $22.45M | (m) | $310.57M | (m) | $112.56M | (m) | (m) | 32.56% | 1.10× |
| 2013-03-31 | $112.75M | (m) | $130.99M | $18.24M | (m) | $309.78M | (m) | $111.39M | (m) | (m) | 36.40% | 1.18× |
| 2012-12-31 | $118.97M | (m) | $132.43M | $13.46M | (m) | $312.41M | (m) | $110.03M | (m) | (m) | 38.08% | 1.20× |
| 2012-09-30 | $114.14M | (m) | $121.58M | $7.44M | (m) | $311.99M | (m) | $110.48M | (m) | (m) | 36.58% | 1.10× |
| 2012-06-30 | $120.73M | (m) | $126.75M | $6.02M | (m) | $314.56M | (m) | $112.33M | (m) | (m) | 38.38% | 1.13× |
| 2012-03-31 | $117.85M | (m) | $124.00M | $6.16M | (m) | $313.92M | (m) | $113.42M | (m) | (m) | 37.54% | 1.09× |
| 2011-12-31 | $116.77M | (m) | $121.93M | $5.16M | (m) | $306.57M | (m) | $112.73M | (m) | (m) | 38.09% | 1.08× |
| 2011-09-30 | $127.25M | (m) | $130.92M | $3.67M | (m) | $299.61M | (m) | $113.45M | (m) | (m) | 42.47% | 1.15× |
| 2011-06-30 | $123.56M | (m) | $127.19M | $3.63M | (m) | $289.96M | (m) | $112.30M | (m) | (m) | 42.61% | 1.13× |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | $106.62M | (m) | $111.26M | $4.64M | (m) | $269.05M | (m) | $109.78M | (m) | (m) | 39.63% | 1.01× |
| 2010-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-06-30 | $104.77M | (m) | $111.32M | $6.56M | (m) | $263.96M | (m) | $105.24M | (m) | (m) | 39.69% | 1.06× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |